ATE339453T1 - Spezifische antikörper für cyp1b1 - Google Patents

Spezifische antikörper für cyp1b1

Info

Publication number
ATE339453T1
ATE339453T1 AT00911087T AT00911087T ATE339453T1 AT E339453 T1 ATE339453 T1 AT E339453T1 AT 00911087 T AT00911087 T AT 00911087T AT 00911087 T AT00911087 T AT 00911087T AT E339453 T1 ATE339453 T1 AT E339453T1
Authority
AT
Austria
Prior art keywords
cyp1b1
cancer
antibodies
specific antibodies
bind
Prior art date
Application number
AT00911087T
Other languages
English (en)
Inventor
William Melvin
Graeme Ian Murray
Original Assignee
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aberdeen filed Critical Univ Aberdeen
Application granted granted Critical
Publication of ATE339453T1 publication Critical patent/ATE339453T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00911087T 1999-03-19 2000-03-20 Spezifische antikörper für cyp1b1 ATE339453T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9906380.2A GB9906380D0 (en) 1999-03-19 1999-03-19 Monoclonal antibodies specific for cypibi

Publications (1)

Publication Number Publication Date
ATE339453T1 true ATE339453T1 (de) 2006-10-15

Family

ID=10849980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911087T ATE339453T1 (de) 1999-03-19 2000-03-20 Spezifische antikörper für cyp1b1

Country Status (10)

Country Link
US (2) US7419794B1 (de)
EP (1) EP1163272B1 (de)
JP (2) JP2002543765A (de)
AT (1) ATE339453T1 (de)
AU (1) AU768885B2 (de)
CA (1) CA2365121A1 (de)
DE (1) DE60030696T2 (de)
ES (1) ES2272261T3 (de)
GB (1) GB9906380D0 (de)
WO (1) WO2000056773A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241945A4 (de) * 1999-11-15 2005-08-17 Dana Farber Cancer Inst Inc Krebs immunotherapie und diagnose unter verwendung von cytochrom p450
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
WO2002042325A2 (en) 2000-10-31 2002-05-30 Zycos Inc. Cyp1b1 nucleic acids and methods of use
US7385023B1 (en) 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
GB0803071D0 (en) 2008-02-20 2008-03-26 Care Technologies Inc Cancer detection methods and techniques
US9101603B2 (en) 2010-11-30 2015-08-11 Institute For Cancer Research Targeting of CYP1B1 in the treatment of head and neck cancer and lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938948A (en) * 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
GB9519490D0 (en) 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use

Also Published As

Publication number Publication date
JP2011157363A (ja) 2011-08-18
WO2000056773A1 (en) 2000-09-28
US7419794B1 (en) 2008-09-02
ES2272261T3 (es) 2007-05-01
EP1163272A1 (de) 2001-12-19
AU768885B2 (en) 2004-01-08
CA2365121A1 (en) 2000-09-28
GB9906380D0 (en) 1999-05-12
EP1163272B1 (de) 2006-09-13
AU3308100A (en) 2000-10-09
JP2002543765A (ja) 2002-12-24
DE60030696T2 (de) 2007-10-04
US20090023160A1 (en) 2009-01-22
DE60030696D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
ATE516047T1 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
NO20026245L (no) Forbedring av antistoff-cytokinfusjonsproteinformidlede immunresponser vedkombinert behandling med immuncytokinopptakforbedrende midler
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
PT1383785E (pt) Anticorpo recombinante específico de tumores e utilização deste
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
DK1893196T3 (da) Diarylhydantoin-forbindelse
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
WO2010060186A8 (en) Antibodies that specifically block the biological activity of a tumor antigen
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
EP2504363A4 (de) Anticlusterin-antikörper und antigenbindende fragmente und ihre verwendung zur reduzierung des tumorvolumens
DE69939819D1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
DE60030696D1 (de) Spezifische antikörper für cyp1b1
ATE425460T1 (de) Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties